Page 1

Exhibit 99.1 Femasys Inc. Announces Financial Results for the Third Quarter of 2021 -- Up to 792 - patient , pivotal LOCAL trial progressing for FemaSeed® after receipt of investigational device exemption ( IDE ) submission approval -- Femasys added to the Russell Microcap® Index in Q3 -- ATLANTA , Nov. 10 , 2021 -- Femasys Inc. ( NASDAQ : FEMY ) , a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive , in - office technologies for reproductive health , today announced financial results for the third quarter and nine months ended September 30 , 2021 and provided a corporate update on the Company's business and clinical programs . " Since becoming public approximately five months ago , we've gained substantial traction for our product candidates that have the opportunity to provide women access to superior technologies and revolutionize their options related to reproductive care , " stated Kathy Lee - Sepsick , president , chief executive officer and founder of Femasys . “ Our pipeline progress has been driven by the advancement of FemaSeed , our novel product candidate that delivers sperm directly to a selected fallopian tube where conception occurs , with enrollment progressing for our LOCAL trial that commenced in July , enrolling qualified women seeking conception at centers across the U.S. with additional centers being added . " Ms. Lee - Sepsick , further commented , " We are now gearing up for the pivotal trial planned for next year associated with our planned IDE submission for FemBlocⓇ , our permanent birth control product candidate . We are eager to address the existing limitations of infertility and birth control options- both vast and underserved markets within women's reproductive health worldwide - with non - surgical solutions that are driven by safety and affordability . " Recent Corporate Developments • On September 20 , 2021 , Femasys announced that the Company was added to the Russell Microcap® Index . The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies . Approximately $ 10.6 trillion in assets are benchmarked against Russell's US indexes . Russell indexes are part of FTSE Russell , a leading global index provider . On September 1 , 2021 , Femasys announced the appointment of Edward G. Evantash , M.D. , as chief medical officer . Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys , having previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic , Inc. , both medical technology companies focused on women's healthcare . He will be responsible for providing leadership and direction for Femasys ' pipeline of clinical development programs .